Hyderabad-based Natco Pharma has launched two cancer drugs- Natfost (Amifostine 500 mg injection) and Hyurea (Hydroxyurea 500 mg. Capsules).
Natfost has the ability to differentially protect normal tissues. It has higher capillary alkaline phosphotase activity, higher pH and better vascularity in relation to tumour tissues, resulting in more rapid generation of active thiol metabolite. The produced is priced at Rs. 700 per vial.
Hyurea, an antineoplastic agent, belongs to the antimetabolites group of medicines. Hydroxyurea is used in the treatment of leukemia, melanoma and colon carcinoma. When used in combination with radiation, Hyurea prevents the cancer cell from repairing itself. A strip of ten capsules of Hyurea is priced at Rs. 135, an official release said.